# OnCo record sinonasal-undifferentiated-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/sinonasal-undifferentiated-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "sinonasal-undifferentiated-carcinoma" ;
  schema:name "Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma"@en ;
  schema:alternateName "SNUC"@en, "IDH2-mutant sinonasal carcinoma"@en, "SMARCB1-deficient sinonasal carcinoma"@en, "SMARCA4-deficient sinonasal carcinoma"@en, "Undifferentiated carcinoma of the paranasal sinuses"@en ;
  schema:description "Sinonasal undifferentiated carcinoma is a rare, fast-growing cancer of the nasal cavity and sinuses made of primitive cells with no clear line of differentiation, most carrying an IDH2 mutation. It presents as a large mass pressing on the eye or brain and is treated with chemotherapy first, then surgery or chemoradiotherapy depending on response; SMARCB1- or SMARCA4-deficient tumours are separate."@en ;
  schema:url <https://onco.cc/cancers/sinonasal-undifferentiated-carcinoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sinonasal_undifferentiated_carcinoma> ;
  schema:citation <https://doi.org/10.1200/JCO.18.00353>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437>, <https://en.wikipedia.org/wiki/Sinonasal_undifferentiated_carcinoma> ;
  onco:tag "subtype-page", "head-and-neck" ;
  onco:related <https://onco.cc/cancers/esthesioneuroblastoma/>, <https://onco.cc/cancers/sinonasal/>, <https://onco.cc/cancers/nut-carcinoma/>, <https://onco.cc/cancers/extrapulmonary-nec/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/pet-ct/> ;
  onco:targets <https://onco.cc/targets/idh/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/enasidenib/> ;
  onco:terms <https://onco.cc/terms/head-neck-subsites/>, <https://onco.cc/terms/rare-cancers/>, <https://onco.cc/terms/chemoradiation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-amit-induction-chemotherapy-response-snuc-jco-2019/>, <https://onco.cc/key-papers/paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017/> ;
  onco:pipeline <https://onco.cc/drugs/enasidenib/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/enasidenib/>, <https://onco.cc/technologies/checkpoint-inhibitor/> .